Novo Nordisk Submits Biologics License Application for Mim8 (Denecimig) in Hemophilia A
Oct 31, 2025, 14:21

Novo Nordisk Submits Biologics License Application for Mim8 (Denecimig) in Hemophilia A

National Bleeding Disorders Foundation (NBDF) shared on LinkedIn:

Novo Nordisk has submitted a Biologics License Application (BLA) for Mim8 (denecimig), a promising bispecific antibody therapy for people with hemophilia A, with or without inhibitors.

Mim8 may offer more flexible dosing options and an easier treatment experience through a single-use, prefilled injector pen.

Learn more about this milestone”

Read the full announcement here.

Novo Nordisk Submits Biologics License Application for Mim8 (Denecimig) in Hemophilia A

Stay updated on the emerging with Hemostasis Today.